Alector, Inc.

NASDAQ:ALEC

Biotechnology

Healthcare
$2.57 +5.13%

+$0.08 today

Market cap
$382.61M
Beta
0.59
P/E (TTM)
-1.4
EPS (TTM)
-$1.13
52W Low $1.09High $3.40

Volume 2.13M

Average 0.65M

ALEC Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Alector, Inc.NASDAQ: ALEC

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $2.91M fell 65.2% year over year, behind the -43.4% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 40.0% from the prior quarter. Over 3 fiscal years it compounded at -16.7% a year.

Context

  • Stock-based compensation amounted to 126.7% of revenue in FY2025, up 87.4 pp from a year earlier.
  • Stock-based compensation increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -65.2% toward the trailing-twelve-month pace of -43.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.91M-40.0% QoQ
Last fiscal yearDec 2025
$26.66M-32.4% YoY
LTMMar 2026
$21.22M-43.4% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-65.2%——
1 year-32.4%——
3-year CAGR-16.7%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
26.66M USD
Year-over-year change
-32.4%
4-year CAGR
-10.1%

Stock-Based Compensation vs competitors

How ALEC compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -43.4% is the 8th highest of 9, against a peer median of -4.9%.
  • Stock-based compensation amounts to 115.2% of revenue for ALEC, versus a peer median of 186.5%.
ALEC Competitors
Stock-Based Compensation for ALEC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VORVor Biopharma Inc.LTM Mar 2026$27.69M USD+218.3%+20.9%—
FATEFate Therapeutics, Inc.LTM Mar 2026$21.47M USD-43.3%-31.8%340.0%
ALECAlector, Inc.LTM Mar 2026$21.22M USD-43.4%-16.7%115.2%
PEPGPepGen Inc.LTM Mar 2026$10.03M USD-22.0%+30.6%—
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$9.77M USD+1.5%+47.6%—
NKTXNkarta, Inc.LTM Mar 2026$7.62M USD-49.8%-20.2%—
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$6.49M USD-5.6%+3.2%—
MOLNMolecular Partners AGLTM Mar 2026CHF 4.21M CHF-4.1%-4.6%—
IRDOpus Genetics, Inc.LTM Mar 2026$3.95M USD+20.1%+23.4%33.0%
Peer median (excluding ALEC) —-4.9%+12.1%186.5%

Competitors are the stored peer set for ALEC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(36.33M)(133.31M)(130.39M)(119.05M)(142.93M)
Depreciation & Amortization8.32M8.47M8.85M8.84M(861K)
Deferred Income Tax00000
Stock-Based Compensation40.79M46.15M42.8M39.46M26.66M
Change in Working Capital283.68M59.53M(90.15M)(146.99M)(74.06M)
Accounts Receivables(7.39M)4.8M2.59M00
Inventory00000
Accounts Payables1.92M(572K)(377K)(1.44M)(524K)
Other Working Capital289.16M55.29M(92.36M)(145.55M)(73.53M)
Other Non-Cash Items2.1M(1.16M)(15.27M)(12.17M)7.16M
Operating Cash Flow298.55M(20.33M)(184.16M)(229.91M)(184.03M)
Capital Expenditures(3.25M)(4.12M)(2.38M)(1.26M)(41K)
Acquisitions (Net)00000
Purchases of Investments(343.4M)(556.9M)(551.73M)(467.74M)(271.88M)
Sales of Investments296.99M402M656.03M576.13M468.52M
Other Investing Activities00000
Investing Cash Flow(49.66M)(159.01M)101.92M107.13M196.6M
Debt Repayment0009.39M0
Common Stock Issued04.51M2.55M71.11M20M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities30.3M001.04M217K
Financing Cash Flow30.3M4.51M2.55M81.54M20.22M
Effect of Forex Changes00000
Net Change in Cash279.18M(174.83M)(79.69M)(41.23M)32.78M
Free Cash Flow295.3M(24.45M)(186.54M)(231.16M)(184.07M)

Alector, Inc.

NASDAQ:ALEC

Intrinsic Alpha fair value

Locked

Current Price

$2.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.